

Joseph M Brandwein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1962322/joseph-m-brandwein-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58
papers

1,990
citations

18
h-index

44
g-index

59
ext. papers

2,336
ext. citations

4.8
avg, IF

4.21
L-index

#	Paper	IF	Citations
58	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. <i>Nature</i> , 2014 , 506, 328-333	50.4	1011
57	Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. <i>British Journal of Haematology</i> , 2009 , 146, 76-85	4.5	114
56	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009 , 114, 1166-73	2.2	113
55	Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. <i>Cancer</i> , 2005 , 103, 2082-90	6.4	75
54	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. <i>Blood</i> , 2020 , 136, 674-683	2.2	67
53	The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. <i>British Journal of Haematology</i> , 1996 , 92, 880-9	4.5	63
52	Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 262-71	3.6	47
51	Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. <i>Journal of Controlled Release</i> , 2016 , 224, 8-21	11.7	34
50	Spontaneous acute tumor lysis syndrome in acute myeloid leukemia? A single case report with discussion of the literature. <i>Leukemia and Lymphoma</i> , 1998 , 29, 625-8	1.9	34
49	Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters. <i>Annals of Hematology</i> , 2016 , 95, 2057-2064	3	32
48	Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia. <i>Molecular Therapy - Nucleic Acids</i> , 2015 , 4, e240	10.7	29
47	Targeting polo-like kinase 1 in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2015 , 6, 80-7	5.7	26
46	Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. <i>American Journal of Hematology</i> , 2008 , 83, 54-8	7.1	22
45	Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. <i>British Journal of Haematology</i> , 2013 , 163, 458-64	4.5	21
44	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019 , 134, 229-229	2.2	19
43	Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. <i>American Journal of Blood Research</i> , 2018 , 8, 29-56	1.6	19
42	A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. <i>Investigational New Drugs</i> , 2016 , 34, 614-24	4.3	18

41	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. <i>British Journal of Haematology</i> , 2012 , 158, 506-14	4.5	18
40	Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 815-24	4.7	18
39	Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. <i>Drug Discovery Today</i> , 2019 , 24, 1355-1369	8.8	17
38	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
37	Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?. <i>Leukemia Research</i> , 2016 , 47, 142-8	2.7	13
36	Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. <i>British Journal of Haematology</i> , 2014 , 167, 664-70	4.5	13
35	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
34	New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 136-142	4.4	12
33	HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-Lymphoma Study Group experience. <i>Leukemia and Lymphoma</i> , 1995 , 16, 343-9	1.9	11
32	Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. <i>American Journal of Blood Research</i> , 2017 , 7, 30-40	1.6	11
31	siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers. <i>Journal of Controlled Release</i> , 2019 , 310, 141-154	11.7	10
30	Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014 , 25, 271-6	2.6	10
29	Treatment of acute lymphoblastic leukemia in adolescents and young adults. <i>Current Oncology Reports</i> , 2011 , 13, 371-8	6.3	10
28	Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. <i>American Journal of Blood Research</i> , 2013 , 3, 141-64	1.6	10
27	Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. <i>British Journal of Haematology</i> , 2020 , 191, 748-754	4.5	9
26	ETV6 /FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia. <i>Journal of Hematopathology</i> , 2014 , 7, 71-77	0.4	9
25	Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study. <i>American Journal of Blood Research</i> , 2020 , 10, 124-133	1.6	5
24	Expanded antigen-experienced CD160CD8effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia 2021 , 9,		5

23	Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy. <i>Blood</i> , 2018 , 132, 3974-3974	2.2	4
22	The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. <i>European Journal of Haematology</i> , 2016 , 97, 471-478	3.8	4
21	Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2016 , 45, 47-52	2.7	4
20	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2021 ,	10.7	4
19	Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen. <i>Leukemia Research</i> , 2014 , 38, 532-6	2.7	3
18	A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. <i>Supportive Care in Cancer</i> , 2019 , 27, 2295-2300	3.9	3
17	Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1991 , 4, 231-8	1.9	2
16	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis. <i>Blood</i> , 2006 , 108, 2007-2007	2.2	2
15	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. <i>Cancer Medicine</i> , 2021 , 10, 6336-6343	4.8	2
14	Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. <i>Hematological Oncology</i> , 2017 , 35, 810-813	1.3	1
13	Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report. <i>Leukemia and Lymphoma</i> , 1993 , 11, 469-72	1.9	1
12	A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020 ,	2.2	1
11	Comparison of Sensitivity of Low-Dose CT Scan and Serum Galactomannan in Patients with Hematologic Malignancies and Positive Bronchoalveolar Lavage for Invasive Pulmonary Aspergillosis. <i>Blood</i> , 2012 , 120, 1490-1490	2.2	1
10	Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 1453-1453	2.2	1
9	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E175-E179	7.1	1
8	Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 121-128	1.9	0
7	CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. <i>Blood</i> , 2020 , 136, 6-7	2.2	0
6	Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL). <i>PLoS ONE</i> , 2021 , 16, e0251719	3.7	0

5	An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E17-E20	7.1	o
4	A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1749-1757	1.9	
3	Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein. <i>Drugs</i> , 2007 , 67, 2655	12.1	
2	Validation of NMT1 and NMT2 As Novel Drug Targets in Adult Acute Myeloid Leukemia: Rationale for N-Myristoyltransferase Inhibition with Pclx-001 for Clinical Trials. <i>Blood</i> , 2021 , 138, 4344-4344	2.2	
1	BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML. <i>Blood</i> , 2019 , 134, 2646-2646	2.2	